211 related articles for article (PubMed ID: 32028967)
1. An NRAS mutation in primary malignant melanoma of the lung: a case report.
Hibiya T; Tanaka M; Matsumura M; Aoki A; Ikegami T; Okudela K; Kawano N; Ohashi K
Diagn Pathol; 2020 Feb; 15(1):11. PubMed ID: 32028967
[TBL] [Abstract][Full Text] [Related]
2. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
Lázár V
Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
[TBL] [Abstract][Full Text] [Related]
3. Tumour mutation status and sites of metastasis in patients with cutaneous melanoma.
Adler NR; Wolfe R; Kelly JW; Haydon A; McArthur GA; McLean CA; Mar VJ
Br J Cancer; 2017 Sep; 117(7):1026-1035. PubMed ID: 28787433
[TBL] [Abstract][Full Text] [Related]
4. Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients.
Sakaizawa K; Ashida A; Uchiyama A; Ito T; Fujisawa Y; Ogata D; Matsushita S; Fujii K; Fukushima S; Shibayama Y; Hatta N; Takenouchi T; Uehara J; Okuyama R; Yamazaki N; Uhara H
J Dermatol Sci; 2015 Oct; 80(1):33-7. PubMed ID: 26282084
[TBL] [Abstract][Full Text] [Related]
5. Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.
Thomas NE; Edmiston SN; Alexander A; Groben PA; Parrish E; Kricker A; Armstrong BK; Anton-Culver H; Gruber SB; From L; Busam KJ; Hao H; Orlow I; Kanetsky PA; Luo L; Reiner AS; Paine S; Frank JS; Bramson JI; Marrett LD; Gallagher RP; Zanetti R; Rosso S; Dwyer T; Cust AE; Ollila DW; Begg CB; Berwick M; Conway K;
JAMA Oncol; 2015 Jun; 1(3):359-68. PubMed ID: 26146664
[TBL] [Abstract][Full Text] [Related]
6. Oncogene abnormalities in a series of primary melanomas of the sinonasal tract: NRAS mutations and cyclin D1 amplification are more frequent than KIT or BRAF mutations.
Chraybi M; Abd Alsamad I; Copie-Bergman C; Baia M; André J; Dumaz N; Ortonne N
Hum Pathol; 2013 Sep; 44(9):1902-11. PubMed ID: 23664541
[TBL] [Abstract][Full Text] [Related]
7. Giant lung metastasis of NRAS-mutant melanoma in a 24-year-old patient with a history of BRAF-mutant conventional melanoma harboring Spitzoid morphology: a case report.
Vachtenheim J; Kodet R; Fischer O; Kolek V; Strizova Z; Ozaniak A; Simonek J; Stolz A; Pozniak J; Kolarik J; Svorcova M; Vachtenheim J; Lischke R
Diagn Pathol; 2020 Oct; 15(1):132. PubMed ID: 33100226
[TBL] [Abstract][Full Text] [Related]
8. Molecular characterization of a selected cohort of patients affected by pulmonary metastases of malignant melanoma: Hints from BRAF, NRAS and EGFR evaluation.
Ulivieri A; Cardillo G; Manente L; Paone G; Mancuso AP; Vigna L; Di Stasio E; Gasbarra R; Girlando S; Leone A
Oncotarget; 2015 Aug; 6(23):19868-79. PubMed ID: 26305188
[TBL] [Abstract][Full Text] [Related]
9. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G
Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428
[TBL] [Abstract][Full Text] [Related]
10. NRAS mutations are more prevalent than KIT mutations in melanoma of the female urogenital tract--a study of 24 cases from the Netherlands.
van Engen-van Grunsven AC; Küsters-Vandevelde HV; De Hullu J; van Duijn LM; Rijntjes J; Bovée JV; Groenen PJ; Blokx WA
Gynecol Oncol; 2014 Jul; 134(1):10-4. PubMed ID: 24802725
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care.
Heppt MV; Siepmann T; Engel J; Schubert-Fritschle G; Eckel R; Mirlach L; Kirchner T; Jung A; Gesierich A; Ruzicka T; Flaig MJ; Berking C
BMC Cancer; 2017 Aug; 17(1):536. PubMed ID: 28797232
[TBL] [Abstract][Full Text] [Related]
12. Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma.
Colombino M; Lissia A; Capone M; De Giorgi V; Massi D; Stanganelli I; Fonsatti E; Maio M; Botti G; Caracò C; Mozzillo N; Ascierto PA; Cossu A; Palmieri G
J Transl Med; 2013 Aug; 11():202. PubMed ID: 23987572
[TBL] [Abstract][Full Text] [Related]
13. KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma.
Zebary A; Omholt K; Vassilaki I; Höiom V; Lindén D; Viberg L; Kanter-Lewensohn L; Johansson CH; Hansson J
J Dermatol Sci; 2013 Dec; 72(3):284-9. PubMed ID: 23993026
[TBL] [Abstract][Full Text] [Related]
14. BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage.
Mar VJ; Wong SQ; Li J; Scolyer RA; McLean C; Papenfuss AT; Tothill RW; Kakavand H; Mann GJ; Thompson JF; Behren A; Cebon JS; Wolfe R; Kelly JW; Dobrovic A; McArthur GA
Clin Cancer Res; 2013 Sep; 19(17):4589-98. PubMed ID: 23833303
[TBL] [Abstract][Full Text] [Related]
15. Prospective evaluation of two screening methods for molecular testing of metastatic melanoma: Diagnostic performance of BRAF V600E immunohistochemistry and of a NRAS-BRAF fully automated real-time PCR-based assay.
Vallée A; Denis-Musquer M; Herbreteau G; Théoleyre S; Bossard C; Denis MG
PLoS One; 2019; 14(8):e0221123. PubMed ID: 31415669
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological characteristics and mutation profile of BRAF and NRAS mutation in cutaneous melanomas in the Western Turkish population.
Evrenos MK; Temiz P; Çam FS; Yaman M; Yoleri L; Ermertcan AT
Turk J Med Sci; 2018 Oct; 48(5):973-979. PubMed ID: 30384563
[TBL] [Abstract][Full Text] [Related]
17. NRAS (Q61R), BRAF (V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas.
Uguen A; Talagas M; Costa S; Samaison L; Paule L; Alavi Z; De Braekeleer M; Le Marechal C; Marcorelles P
Diagn Pathol; 2015 Jul; 10():121. PubMed ID: 26204954
[TBL] [Abstract][Full Text] [Related]
18. Mutational Status of NRAS and BRAF Genes and Protein Expression Analysis in a Series of Primary Oral Mucosal Melanoma.
Hsieh R; Nico MM; Camillo CM; Oliveira KK; Sangueza M; Lourenço SV
Am J Dermatopathol; 2017 Feb; 39(2):104-110. PubMed ID: 28134726
[TBL] [Abstract][Full Text] [Related]
19. Malignant Melanoma of Vulva and Vagina: A Histomorphological Review and Mutation Analysis--A Single-Center Study.
Rouzbahman M; Kamel-Reid S; Al Habeeb A; Butler M; Dodge J; Laframboise S; Murphy J; Rasty G; Ghazarian D
J Low Genit Tract Dis; 2015 Oct; 19(4):350-3. PubMed ID: 26225944
[TBL] [Abstract][Full Text] [Related]
20. Time and tumor type (primary or metastatic) do not influence the detection of BRAF/NRAS mutations in formalin fixed paraffin embedded samples from melanomas.
Potrony M; Badenas C; Naerhuyzen B; Aguilera P; Puig-Butille JA; Tell-Marti G; Díaz A; Carrera C; Alos L; Delahaye N; Malvehy J; Puig S
Clin Chem Lab Med; 2016 Nov; 54(11):1733-1738. PubMed ID: 27101548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
